Thoracic solid tumour resectability in the ERA of Immunotherapy
Authored by Andrea Billè, published on 2026-04-14 03:49:37.0
Resectability Matrix in the ERA of ImmunotherapyThere is no consensus reached for some stage features. Resectability decision making is key for patient to be eligible for chemo Immunotherapy. There are guidelines but there is no algorithm to help tumour board or surgeons to define resectability in N2 category or locally advanced cancer (T3 / T4).
N1 and N2 lymph node station involved, specifying location
The porpoise is to introduce the stations involved, the number and also if they are bulky or not
Offer resectability options, in terms of operation
base on tumor location patient may have: a lobectomy, a bilobectomy a pneumonectomy or an ertrial or bronchial slleve
Neo adjuvant Chemo and Immunotherapy
Surgery
Perioperative Immunotherapy
Chemo RT
Immunotherapy
Salvage surgery
Consider re staging before offer surgery
Insert maximum tumor size and or extension and structured invaded in case of a T4 tumour
Offer resectability options, in terms of operation
base on tumor location patient may have: a lobectomy, a bilobectomy a pneumonectomy or an ertrial or bronchial slleve